Homepage Top Section2

IFM Tre, which was launched in July 2018, is currently developing a suite of NLRP3 antagonists for the treatment of inflammatory diseases. NLRP3, which expands to NOD-, LRR-

The early-stage trial is assessing the safety and efficacy of the ipatasertib combination in patients with locally advanced or metastatic triple-negative breast cancer who previously did not receive

As part of the global development and commercialization collaboration, AstraZeneca and Daiichi Sankyo will develop and commercialize trastuzumab deruxtecan (DS-8201), which is an antibody-drug conjugate (ADC) and potential

The multimillion-pound drug discovery alliance will bring together Cancer Research UK’s network of scientists and drug discovery expertise, LifeArc’s therapeutic antibody engineering and development expertise and Ono’s expertise

Mayzent is claimed to the first oral drug to treat secondary progressive MS with active disease. Mayzent is approved across the MS spectrum for clinically isolated syndrome (CIS),

Owned by Ampersand Capital Partners, Brammer Bio is engaged in the clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy.

Pfizer has paid around €45m ($51m) to purchase a 15% equity interest in Vivet Therapeutics, and will pay up to €560m that includes option exercise payment and certain

The public-private partnership between Evotec and GARDP will strive to address the increasing threat of antimicrobial resistance (AMR). It will combine GARDP’s clinical expertise and Evotec’s drug discovery

Tecentriq monoclonal antibody has been approved in combination with carboplatin and etoposide as a first-line treatment for adults with ES-SCLC. The approval was based on data from the